| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTHR2 |
| Uniprot No | P49190 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-145aa |
| 氨基酸序列 | DSDGTITIEEQIVLVLKAKVQCELNITAQLQEGEGNCFPEWDGLICWPRGTVGKISAVPCPPYIYDFNHKGVAFRHCNPNGTWDFMHSLNKTWANYSDCLRFLQPDISIGKQEFFERLY |
| 预测分子量 | 29.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTHR2(Parathyroid Hormone Receptor 2)重组蛋白的模拟参考文献示例(文献信息为虚构，仅供格式参考)：
1. **文献名称**: "Cloning and Functional Characterization of the Parathyroid Hormone Receptor 2 (PTHR2) in Mammalian Cells"
**作者**: Hoare SRJ, et al.
**摘要**: 研究报道了PTHR2受体的重组表达及功能分析，通过体外实验验证其与配体PTHrP(甲状旁腺激素相关蛋白)的结合特性，并揭示其在cAMP信号通路中的激活机制。
2. **文献名称**: "Structural Insights into PTHR2 Activation by Cryo-EM"
**作者**: Zhang Y, et al.
**摘要**: 利用冷冻电镜解析PTHR2重组蛋白与配体结合的复合物结构，阐明受体跨膜结构域的构象变化及G蛋白偶联机制，为靶向药物设计提供依据。
3. **文献名称**: "PTHR2-Mediated Signaling in Bone Development: Role of Recombinant Protein Mutants"
**作者**: Tian L, et al.
**摘要**: 通过构建PTHR2重组蛋白突变体，研究其在成骨细胞分化中的作用，发现特定结构域缺失导致下游MAPK通路异常，影响骨代谢调控。
4. **文献名称**: "Expression and Purification of Recombinant PTHR2 for Therapeutic Antibody Screening"
**作者**: Kumar A, et al.
**摘要**: 开发高效昆虫细胞表达系统纯化PTHR2重组蛋白，应用于高通量筛选拮抗性抗体，探索其在肿瘤相关高钙血症治疗中的潜力。
**注意**：以上文献信息为模拟生成，实际研究中请通过PubMed、Web of Science等数据库检索真实文献。
**Background of PTHR2 Recombinant Protein**
The parathyroid hormone receptor 2 (PTHR2), also known as PTH2R, is a class B G protein-coupled receptor (GPCR) that plays a critical role in regulating calcium homeostasis, bone metabolism, and neuroendocrine signaling. It is activated primarily by parathyroid hormone (PTH) and, in some species, by tuberoinfundibular peptide of 39 residues (TIP39). Unlike its closely related homolog PTH1R, PTHR2 exhibits distinct ligand specificity and tissue distribution, with high expression in the central nervous system, pancreas, and testis, suggesting roles beyond mineral ion regulation.
Recombinant PTHR2 protein is engineered *in vitro* using expression systems like mammalian cells (e.g., HEK293) or insect cells to ensure proper post-translational modifications and functional folding. This allows researchers to study its structure, ligand-binding mechanisms, and downstream signaling pathways (e.g., Gαs/cAMP and Gαq/calcium) in controlled environments. Structural studies using recombinant PTHR2. often coupled with cryo-EM or X-ray crystallography, have revealed conformational changes during receptor activation, aiding the design of selective agonists or antagonists.
PTHR2 is implicated in pathological conditions, including hypercalcemia, osteoporosis, and neuropsychiatric disorders. Its recombinant form is vital for drug screening, particularly for therapies targeting bone diseases or neurological pathways. Additionally, it serves as a tool to investigate cross-talk with other receptors (e.g., PTH1R) and its role in developmental biology.
Overall, recombinant PTHR2 bridges molecular insights with translational applications, offering a platform to decode its physiological impact and therapeutic potential.
×
